Acute Renal Failure during Therapy with Recombinant Human Gamma Interferon

New England Journal of Medicine

Volumn 319, Issue 21, 1988, Pages 1397-1400

  Ault, Bettina H ^a   Stapleton, F Bruder ^a   Gaber, Lillian ^a   Martin, Alison ^a   Roy, Shane ^a   Murphy, Sharon B ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON;

ACUTE KIDNEY FAILURE; CASE REPORT; CHILD; GLOMERULUS; HISTOLOGY; HUMAN; LYMPHATIC LEUKEMIA; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; ULTRASTRUCTURE;

EID: 0023691392     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJM198811243192107     Document Type: Article

References (14)

1. Krown SE. Interferons and interferon inducers in cancer treatment. Semin Oncol 1986; 13: 207–17.
2. Goldstein D, Laszlo J. Interferon therapy in cancer: from imaginon to interferon. Cancer Res 1986; 46: 4315–29.
3. Talpaz M, Kantarjian HM, Kurzrock R, Gutterman J. Therapy of chronic myelogenous leukemia: chemotherapy and interferons. Semin Hematol 1988; 25: 62–73.
4. Kaplan EH, Rosen ST, Norris D, Roenigk H Jr, Saks S, Bunn PA Jr. Phase II trial of recombinant human interferon-gamma in cutaneous T-cell lymphoma. Proc Am Soc Clin Oncol 1988; 7: 226. abstract.
5. Averbuch SD, Austin HA III, Sherwin SA, Antonovych T, Bunn PA Jr, Longo DL. Acute interstitial nephritis with the nephrotic syndrome following recombinant leukocyte A interferon therapy for mycosis fungoides. N Engl J Med 1984; 310: 32–5.
6. Gagliano RG, Costanzi JJ, Beathard GA, Sarles HE, Bell JD. The nephrotic syndrome associated with neoplasia: an unusual paraneoplastic syndrome: report of a case and review of the literature. Am J Med 1976; 60: 1026–31.
7. Dosa S, Phillips TM, Antonovych TT, Segal A, Guha A, Thompson AM. Acute myelomonocytic leukemia associated with nephrotic syndrome: a case report with immunological studies. Nephron 1983; 34: 125–9.
8. Feldman D, Goldstein AL, Cox DC, Grimley PM. Cultured human endothelial cells treated with recombinant leukocyte A interferon. Tubuloreticular inclusion formation, antiproliferative effect, and 2'-5' oligoadenylate synthetase induction. Lab Invest 1988; 58: 584–9.
9. Kurzrock R, Quesada JR, Talpaz M, et al. Phase I study of multiple dose intramuscularly administered recombinant gamma interferon. J Clin Oncol 1986; 4: 1101–9.
10. Quesada JR, Talpaz M, Rios A, Kurzrock R, Gutterman JU. Clinical toxicity of interferons in cancer patients: a review. J Clin Oncol 1986; 4: 234–43.
11. Selby P, Kohn J, Raymond J, Judson I, McElwain T. Nephrotic syndrome during treatment with interferon. Br Med J 1985; 290: 1180.
12. Gresser I, Maury C, Tovey M, Morel-Maroger L, Pontillon F. Progressive glomerulonephritis in mice treated with interferon preparations at birth. Nature 1976; 263: 420–2.
13. Gresser I, Aguet M, Morel-Maroger L, et al. Electrophoretically pure mouse interferon inhibits growth, induces liver and kidney lesions, and kills suckling mice. Am J Pathol 1981; 102: 396–402.
14. Morel-Maroger L, Sloper JC, Vinter J, Woodrow D, Gresser I. An ultrastructural study of the development of nephritis in mice treated with interferon in the neonatal period. Lab Invest 1978; 39: 513–22.